Tom H. M. Ottenhoff;Rienk Offringa;Cornelis Johannes Maria Melief;Sjoerd Hendrikus Van Der Burg;Annemieke M. De Jong;Annemieke Geluk;Maria Johanna Philomena Schoenmaekers-Welters;Rene Everardus Maria
发明人:
Sjoerd Hendrikus Van Der Burg,Tom H. M. Ottenhoff,Annemieke Geluk,Maria Johanna Philomena Schoenmaekers-Welters,Annemieke M. De Jong,Rienk Offringa,Cornelis Johannes Maria Melief,Rene Everardus Maria
申请号：
US11712199
公开号：
US09115185B2
申请日:
2007.02.28
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides. The invention further provides clinically relevant approaches for vaccination and/or treatment of subjects against HPV. The invention also provides methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer.
